865624-17-5 Usage
General Description
Benzene, 1-(bromomethyl)-3-chloro-5-nitro- is a chemical compound that consists of a benzene ring with a bromomethyl group, a chlorine atom, and a nitro group attached. It is a derivative of benzene that is commonly used as a building block in the synthesis of various organic compounds. BENZENE, 1-(BROMOMETHYL)-3-CHLORO-5-NITRO- is commonly used in the production of pharmaceuticals, agrochemicals, and industrial chemicals. It is important to handle this compound with care as it is potentially harmful if it comes into contact with the skin, eyes, or if it is inhaled. It is also important to follow proper safety protocols when handling and storing this chemical to prevent any accidents or exposure.
Check Digit Verification of cas no
The CAS Registry Mumber 865624-17-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,5,6,2 and 4 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 865624-17:
(8*8)+(7*6)+(6*5)+(5*6)+(4*2)+(3*4)+(2*1)+(1*7)=195
195 % 10 = 5
So 865624-17-5 is a valid CAS Registry Number.
InChI:InChI=1/C7H5BrClNO2/c8-4-5-1-6(9)3-7(2-5)10(11)12/h1-3H,4H2
865624-17-5Relevant articles and documents
DEOXYNOJIRIMYCIN DERIVATIVES AS GLUCOSIDASE INHIBITORS
-
Paragraph 0848, (2022/01/22)
The present invention relates to novel iminosugars and their use as glucosidase inhibitors. The present inventors discovered that certain deoxynojirimycin derivatives may be effective in inhibiting glucosidases. In particular, such deoxynojirimycin derivatives may be useful for treating a disease or condition in which inhibition of glucosidase may play an important role.
THYROID RECEPTOR AGONISTS
-
Page/Page column 66, (2010/02/14)
The invention provides compounds of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition mediated by a thyroid receptor. Formula (I), wherein R1, R2, n, Y, Y', R3, R4, W and R5 are as defined in the specification.
